- Home
- PRQR vs SOR Comparison
PRQR vs SOR Comparison
Compare PRQR & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | SOR |
|---|---|---|
| Founded | 2012 | 1968 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 391.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | SOR |
|---|---|---|
| Price | $2.04 | $46.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.14 | N/A |
| AVG Volume (30 Days) | ★ 672.3K | 16.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 6.50 |
| Revenue | ★ $18,859,556.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.56 | N/A |
| P/E Ratio | ★ N/A | $6.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $36.41 |
| 52 Week High | $3.10 | $42.75 |
Technical Indicators
Market Signals| Indicator | PRQR | SOR |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 39.59 |
| Support Level | $1.91 | $46.83 |
| Resistance Level | $2.31 | $47.75 |
| Average True Range (ATR) | 0.17 | 0.94 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 21.74 | 0.00 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.